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CASE REPORT
A 27-year-old man was referred to the ENT clinic with 
a mass in the right external ear canal. He had no past 
medical history of note. Presenting symptoms included 
bloody otorrhoea, otalgia and decreased hearing in the 
right ear for 2 months. On examination the presence of 
a large polyp was confirmed. The tympanic membrane 
could not be visualised owing to the size of the polyp. 
The left ear appeared normal. The biopsy showed 
inflamed, partly necrotic granulation tissue, reported 
as a pyogenic granuloma. A trial of steroid-antibiotic 
ointment was commenced.
The patient’s symptoms persisted, and he was booked 
for an examination under anaesthesia. Clinically he 
was pyrexial, with worsening otitis externa and a 
recurring polypoid mass formation with large, pale 
granulations. Biopsy resulted in profuse bleeding. 
The differential diagnosis was tuberculosis or glomus 
tympanicum. Laboratory investigations revealed an 
erythrocyte sedimentation rate of 60 mm/h but a 
normal peripheral white cell count. He had no clinical 
evidence of pulmonary disease and a chest radiograph 
appeared normal. There was no other apparent source 
of infection. Histological examination revealed an 
acute inflammatory response with no granulomas, and 
a Ziehl-Neelsen stain was negative. An HIV test showed 
the patient to be HIV infected. Anti-tuberculosis (TB) 
medication was commenced empirically and a repeat 
biopsy was taken. The patient’s pyrexia resolved and he 
was subsequently discharged.
The patient was lost to follow-up and presented again 
3 months later. A necrotic polyp occluding the external 
ear canal was still evident. Biopsy taken at the previous 
presentation suggested a possible cholesteatoma. All 
specimens sent for TB culture were negative. The 
CD4 count from the previous admission was 24 cells/
µl. An urgent temporal bone computed tomography 
(CT) scan revealed opacifications in the middle ear 
and mastoid cavity with the ossicles and scutum still 
intact, making the diagnosis of cholesteatoma less 
likely. The most recent biopsy showed granulation 
tissue, suppurative inflammation, focal giant cells, 
fibrin and copious amounts of foamy exudates. Special 
stains were performed to exclude other pathologies. 
Ziehl-Neelsen and Brown and Brenn stains were 
again non-contributory, but a Grocott-Gomori 
methenamine-silver stain (Fig. 1) showed the presence 
of Pneumocystis cysts confirming a diagnosis of otic 
pneumocystosis. The patient was commenced on high 
doses of oral trimethoprim-sulfamethoxazole and 
referred to the HIV clinic for initiation of highly active 
antiretroviral therapy. During a telephonic conversation 
2 months later he reported symptomatic improvement. 
The otorrhoea and pain had subsided but he still had 
hearing loss. 
DiSCuSSiOn 
Pneumocystis jirovecii infection is an important 
opportunistic infection. The organism was discovered in 
1909 by Chagas, but the cystic forms were mistakenly 
considered to be part of the trypanosome life cycle. 
It was named P. carinii (Greek: pneumon ‘lung’, kystis 
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Pneumocystis jirovecii is well known to cause interstitial plasma cell pneumonia in immunocompromised 
patients. It has been implicated as a rare cause of infections in other anatomical sites.1 We report a rare case 
of P. jirovecii infection of the external auditory canal. This was the first manifestation of a previously unknown 
HIV infection.
S E P T EMB E R   2 0 1 0                                                     T H E  S O U T H E R N  A F R I C A N  J O U R NA L  O F  H I V  M E D I C I N E 
‘cyst’).2 Until 1988 the organism was considered to be a 
protozoan. The controversy regarding its taxonomy and 
classification continued for decades and recently, based 
on ribosomal RNA homologous to that found in fungi,2 
it was re-classified as a fungus. Advances in molecular 
technology led to Pneumocystis organisms infecting 
humans being re-named P. jirovecii in 1999.3 
P. jirovecii infection is an important opportunistic 
infection, and the incidence of pneumocystis pneumonia 
is on the increase in sub-Saharan Africa. Extrapulmonary 
pneumocystosis is, however, a rare complication and 
represents less than 1% of all cases of infection.4 One 
or more tissue or organ sites may be involved, with the 
most common being lymph nodes, bone marrow, spleen 
and liver. Otic pneumocystosis is exceedingly rare. It 
has only been described in the past 2 decades, and up 
to 2008 only 14 cases had been reported in the English 
literature.3 
It is postulated that under favourable conditions 
extrapulmonary dissemination can occur via the 
lymphatic and haematogenous routes.4 One theory is 
that these individuals may have more virulent strains. 
Observations in rat models suggest that heavy organism 
load and destruction of lung tissue may contribute 
to extrapulmonary dissemination.5 Conversely, P. 
jirovecii infection may be a systemic disease that most 
commonly affects the lungs. Extrapulmonary infection 
becomes more evident when prophylaxis is focused 
on the respiratory tract, and this may explain the 
correlation with the use of aerosolised prophylactic 
pentamidine.1,4 
Although the mechanism of primary otic pneumocystosis 
is as yet unclear, it has been suggested that it may 
follow airborne invasion by trophozoites of the external 
auditory canal6 and that the middle ear may become 
involved after spread from nasopharyngeal carriage via 
the eustachian tube.
Individuals with otic pneumocystosis may have 
nonspecific symptoms of otorrhoea, otalgia, hearing 
loss, vertigo and tinnitus. Clinical findings include a 
mass in the external auditory canal and occasional otitis 
media. Destruction of the ossicles and sclerosis of the 
mastoid air cells, extensive bony erosion, and extension 
into the middle cranial fossa are rare complications 
documented in the literature.3 
Diagnosis can be confirmed by biopsy, which is 
essential to rule out malignancy or other infective 
pathogens.6 Organisms can be demonstrated on 
microscopic examination of tissue sections and 
cytological preparations using silver, fluorescent or 
immunoperoxidase staining methods. The standard 
method using a Grocott-Gomori methenamine-silver 
stain is easy and reliable. Cystic forms are round to 
oval, 4 - 7 µm in dimension, and appear as collapsed 
crescent- or helmet-shaped forms. The granulomatous 
reaction is composed of trophozoites and cysts, which 
appear as basophilic dots on H&E. There is a variable 
inflammatory infiltrate.
As for pulmonary pneumocystis, medical therapy consists 
of oral or intravenous trimethoprim/sulfamethoxazole. 
Other regimens described include dapsone/trimethoprim, 
clindamycin/primaquine, atovaquone and pentamidine 
isethionate.1,3 Although there is usually resolution of 
symptoms after medical therapy, surgical excision of 
lesions in the external auditory canal may be clinically 
indicated. 
Disseminated pneumocystosis, like Pneumocystis 
pneumonia, has high mortality rates. The prognosis 
may be better for those with single extrapulmonary site 
involvement and no concomitant lung infection.4 It is 
important for health care professionals to be aware of 
this infection as the HIV pandemic continues and results 
in common infections manifesting in extraordinary 
ways and in unusual sites.
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Fig. 1. Grocott-Gomori methenamine-silver stain showing 
Pneumocystis cysts of variable shape and size  
(40 × magnification).
